# Is Semaglutide Safe for People With HIV? Four Studies So Far | This GLP Is semaglutide safe for people with HIV? Four studies found no new safety problem | visceral fat fell 30.6% in a trial and depression scores did not worsen. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Is Semaglutide Safe for People With HIV? Four Studies So Far A 108-person trial and two routine-care cohorts found no new safety problem. Visceral fat fell 30.6%, weight fell 6.47 kg, and depression scores did not worsen. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Semaglutide in people with HIV, four reports · Trial, 108 people · visceral fat · -30.6% · Same trial · visuospatial score · improved · Cohort, 222 people · weight at 1 year · -6.47 kg · Cohort, 354 people · depression score · -0.1 · The largest group is 354 people. A rare harm needs far more. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four published studies of semaglutide in people with HIV have found no new safety problem. The largest followed 354 people. - In a 32-week randomized trial of 108 people, visceral fat fell 30.6% against placebo. Adverse event rates did not differ significantly. - The same trial recorded one semaglutide-related grade 4 lipase elevation and two possibly related gallstone cases. - In a cohort of 222 people, 97% on antiretroviral therapy, weight fell 6.47 kg at one year. - Depression scores did not worsen overall: a change of -0.1 points across 354 people. So far, yes, within limits. Four published studies have found no new safety problem. The largest followed 354 people. That is enough to see common effects. It is not enough to see rare ones. The evidence comes in two kinds. One randomized trial compared semaglutide with placebo. It was reported twice, once for body fat and once for cognition. Two cohorts followed people starting semaglutide in routine HIV care. Mood is covered for the general population in [the depression and anxiety guide](https://thisglp.com/research/do-glp1-drugs-cause-depression). This page covers the HIV-specific record. ## The trial: 108 people, 32 weeks The trial enrolled people with controlled HIV-1 and a BMI of 25 or more [\[1\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-1). All had lipohypertrophy, a build-up of abdominal fat. Nobody had diabetes. Participants were randomized 1:1. The semaglutide dose rose over 8 weeks and then held at 1.0 mg weekly for 24 weeks. Visceral fat fell 30.6% against placebo. Total body fat fell 18.9%. Eight people in each arm, 15%, withdrew early. Adverse event rates did not differ significantly between arms. Three events are named in the results. One grade 4 lipase elevation was judged related to semaglutide. Two cases of gallstones, grades 1 and 2, were judged possibly related. Pancreas and gallbladder events across the drug class are covered in [the pancreatitis guide](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis) and [the gallbladder evidence](https://thisglp.com/research/glp1-and-gallbladder-disease). The authors call for larger trials to examine serious adverse events. ## Cognition in the same trial A second report measured thinking skills in the same 108 people [\[2\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-2). Against placebo, three scores rose at 32 weeks. They were visuospatial, naming and language, and delayed recall. After adjusting for sex and CD4 count, only visuospatial stayed significant. The wider question sits in [the dementia evidence](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia). ## Routine care: weight and blood sugar A US cohort followed 222 people with HIV who started semaglutide [\[3\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-3). At baseline, 97% were on antiretroviral therapy. 89% had a suppressed viral load. 77% had diabetes. Mean follow-up was 1.1 years. Weight fell 6.47 kg at one year. HbA1c fell 1.07 points in the 157 people with a follow-up test. The authors call both results comparable to the general population. ## Routine care: depression scores Depression is common in people with HIV. A second cohort asked whether semaglutide made it worse [\[4\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-4). It followed 354 people across nine clinic sites. Scores came from a standard nine-item questionnaire collected at routine visits. The overall change was -0.1 points. The 95% confidence interval ran from -0.7 to 0.5. No subgroup worsened by BMI, diabetes or antidepressant use. The subgroups moved toward the middle Scores rose 1.2 points in people who started with few symptoms. They fell 4.7 points in people who started severe. The study had no control group. Extreme scores drift toward the average on a second measurement with or without a drug. Neither figure is a treatment effect. That limit matches other psychiatric evidence on this site. See [the bipolar cohort](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder) and [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding). ## What the four studies do not cover The trial excluded people with diabetes. Every study group had controlled or treated HIV. The largest group was 354 people. A harm affecting one person in a thousand would likely go unseen. A prescriber who knows the full medication list is the right check before starting. ## Frequently asked Is semaglutide safe for people with HIV? Four published studies found no new safety problem. The randomized trial had 108 people and the largest cohort 354, which is too small to detect a rare harm. Does semaglutide help HIV-associated belly fat? In a 32-week randomized trial of people with HIV-associated lipohypertrophy, visceral fat fell 30.6% against placebo and total body fat fell 18.9%. What side effects were seen in people with HIV? Adverse event rates did not differ significantly from placebo. The trial recorded one grade 4 lipase elevation judged related to semaglutide and two possibly related gallstone cases. Does semaglutide make depression worse in people with HIV? Not in a 354-person routine-care cohort. The overall change in depression score was -0.1 points, 95% CI -0.7 to 0.5, and no subgroup worsened. Does semaglutide work for weight loss in people with HIV? In a cohort of 222 people, 97% on antiretroviral therapy, weight fell 6.47 kg at one year. The authors called that comparable to the general population. ## Sources 1. \[1\] Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, et al. (2024). Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial The Lancet Diabetes & Endocrinology. [PMID 38964353](https://pubmed.ncbi.nlm.nih.gov/38964353/) 2. \[2\] Atieh O, Daher J, Abboud M, Wu Q, Sattar A, Baissary J, et al. (2026). Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial Clinical Infectious Diseases. [PMID 41098140](https://pubmed.ncbi.nlm.nih.gov/41098140/) 3. \[3\] Haidar L, Crane HM, Nance RM, Webel A, Ruderman SA, Whitney BM, et al. (2024). Weight loss associated with semaglutide treatment among people with HIV AIDS. [PMID 37976053](https://pubmed.ncbi.nlm.nih.gov/37976053/) 4. \[4\] Haidar L, Ruderman SA, Leong C, Doupe MB, Lesko C, Delaney JAC (2026). Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care AIDS. [PMID 42558052](https://pubmed.ncbi.nlm.nih.gov/42558052/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness)